TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03627585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalised programming
Description: Reprogramming protocol already test in an observation cohort will be utilised which will direct physiologists to consider pacemaker mode, base rate, utilisation of rate response, hysteresis, sleep and rest rates as well as lead outputs.
Study: NCT01541150

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: neuropsychological questionnaires
Description: Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: neuropsychological questionnaires
Description: Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
Study: NCT02007122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceftaroline in CRRT
Description: Plasma levels of ceftaroline will be measured in patients receiving CRRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ceftaroline in IRRT
Description: Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
Study: NCT00590408

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coenzyme Q10
Description: 60mg capsule twice daily for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo capsule twice daily for 12 weeks
Study: NCT01167309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 27847
Description: First in patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 27847
Description: First in patient

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 27847
Description: First in patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 27847
Description: First in patient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 27847
Description: First in patient
Study: NCT04117841

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.

Intervention type: OTHER
Intervention: Observational
Description: All groups will undergo observational data collection. No interventions will be made to patient care.
Study: NCT03435705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintaining of occupational therapy
Description: 8 home sessions over a 4 months period with caregivers' education, occupational therapy and care coordination for post intervention
Study: NCT00086762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MR Therapy
Description: Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxing Music (RM) Therapy
Description: Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Symptom Management
Description: Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
Study: NCT01702584

Intervention type: PROCEDURE
Intervention: stent assisted embolization
Description: stent assisted embolization and anti-thrombotic management
Study: NCT03252353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: octreotide capsules
Description: octreotide capsules 40 mg/day, 60 mg/day, 80 mg/day (individual dose titration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo capsules
Study: NCT04520386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMT-111
Description: Pre-filled Syringe
Study: NCT01740219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Enhancement
Description: Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dissemination
Description: Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
Study: NCT03819049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC10V
Description: Participants will receive a single IM injection of ExPEC10V (1 of 3 doses \[low or medium or high\]) in Cohort 1 and ExPEC10V selected dose (based on the primary analysis results of Cohort 1) in Cohort 2 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ExPEC4V
Description: Participants will receive a single IM injection of ExPEC4V on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13
Description: Participants will receive a single IM injection of Prevnar 13 on Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single IM injection of matching placebo on Day 1.
Study: NCT01809171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: ampoule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ampoule
Study: NCT04191057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free light chains
Description: Blood samples will be collected and analyzed
Study: NCT02417636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task Shifting
Description: Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task Shifting
Description: Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 12months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
Study: NCT00323193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVE!
Description: group based psychoeducation, motivation and support
Study: NCT03467165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: MRgFUS treatment of pain caused by trapeziometacarpal OA (and/or scaphotrapezial OA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS treatment
Description: MRgFUS treatment of pain caused by hip OA
Study: NCT00980538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
Study: NCT01089699

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online support group
Description: online support group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online support group
Description: online support group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: home study support materials
Description: self-study materials
Study: NCT04456478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pH at 7.38 ± 0.02
Description: In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.38 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pH at 7.22 ± 0.02
Description: In the 3 centers of the study, IVF-ICSI will be performed according to the usual procedure: ovarian stimulation, oocyte retrieval, sperm microinjection by ICSI, embryo culture in Global® Total HSA medium, embryo selection and transfer at day 3. The day of the oocyte puncture, the embryologist will proceed to the 1: 1 randomization: culture of the embryos in a medium with a pH at 7.22 ± 0.02. We have chosen to study specifically the early stages of fertilization and embryo development (until day 3), stages for which extracellular pH control is more critical because the intracellular pH regulatory mechanisms are somewhat limited and could be exceeded.
Study: NCT01548677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
Study: NCT01581970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab 400 mg/m\^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m\^2 intravenously (IV) over 60 minutes.
Study: NCT04296149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y90-DOTA-Tyr3-Octreotide
Description: Patients enrolled for surgery will receive a small amount of Y-90-DOTATOC, in order to check beta- radioactivity by the probe
Study: NCT02045927

Intervention type: OTHER
Group type: OTHER
Intervention: sedation monitoring with RASS score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedation monitoring with RASS score

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sedation monitoring with BIS-Guided monitoring
Study: NCT01826123

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laboratory testing (Central laboratory)
Description: aPTT, INR, fibrinogen concentration, platelet count

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POC testing
Description: ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
Study: NCT01521988

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atrial flutter ablation
Description: Radiofrequency ablation of Atrial flutter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial flutter ablation and pulmonary vein isolation
Description: Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
Study: NCT04548440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Route of administration: Intravenously over 30min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Route of administration: Intravenous
Study: NCT00970697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: becaplermin gel
Description: the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duoderm Hydrogel™
Description: The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
Study: NCT01575223

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeilMed sinus rinse
Description: High volume saline irrigation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Salinex
Description: Low volume saline irrigation
Study: NCT01038791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heated humidification
Description: temperature 35°

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heat and moisture exchanger
Description: single patient device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: usual mechanical ventilation without humidification
Description: mechanical ventilation with usual parameters
Study: NCT00411203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen Citrate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01799798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
Study: NCT02939729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking Programme
Description: Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer
Description: An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises
Description: Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
Study: NCT01459003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: beauty care
Description: beauty care performed before each chemo cycle
Study: NCT03931876

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Single ascending dose administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AV-006
Description: Single ascending dose administration
Study: NCT00721604

Intervention type: DRUG
Intervention: fluid administration
Description: two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
Study: NCT02946125

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MDD-administered EYN-1601
Description: Phenylephrine hydrochloride ophthalmic solution 10% formulated for microdose spray delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 2.5% Eyedrop
Description: Phenylephrine hydrochloride ophthalmic solution 2.5% eyedrop

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine 10% Eyedrop
Description: Phenylephrine hydrochloride ophthalmic solution 10% eyedrop
Study: NCT02696070

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant Therapy System

Intervention type: DEVICE
Group type: OTHER
Intervention: Provant Therapy System
Study: NCT03700242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HDCV
Description: Pharmaceutical form:Solution for injection Route of administration: Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PVRV
Description: Pharmaceutical form:Solution for injection Route of administration: Intradermal
Study: NCT02161913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Family Group Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCI Education Control Group
Study: NCT04807621

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet transfusion
Description: Platelets (10 ml/kg body weight) is transfused.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Description: Fibrinogen concentrate (300 mg/kg body weight) is administered.
Study: NCT01465477

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated split virion Influenza vaccine
Description: WHO recommended 2011 Influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WHO recommended 2011 Influenza vacccine
Description: WHO recommended 2011 Influenza vacccine
Study: NCT04761731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF®
Description: Administration method The total daily dose of tacrolimus will be converted to 1:1 (mg:mg) and the total daily dose of ADVAGRAF® will be administered only once daily in the morning, starting from Day 1 (at least one hour before breakfast or 2 to 3 hours after breakfast).~* Dose adjustment after conversion On Day 1, the total dose will be converted to 1:1. It is recommended to check the blood concentration of tacrolimus at each visit and adjust the dose to achieve the blood concentration maintaining at 5\~8ng/ml for 0 to 3 months and then at 5ng/ml or below for 3 to 6 months of study treatment.~* Duration of treatment The investigational product will be administered for 24 weeks.
Study: NCT03556566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tableted vaccine (V3-OVA) containing ovarian cancer antigens
Description: One pill of V3-OVA per day for three months
Study: NCT03291548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quinoa biscuit
Description: 2x15g biscuits per day for 28 consecutive days (4 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control biscuit
Description: 2x15g biscuits per day for 28 consecutive days (4 weeks).
Study: NCT01444443

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop control
Description: Blood glucose controlled by algorithm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop control
Description: Blood glucose controlled by patient
Study: NCT02339233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standing and Stepping with spinal cord Epidural Stimulation
Description: Standing and Stepping with support from trainers as needed, overground or in a harness with body weight support on a treadmill. Epidural stimulation with specific configurations will be administered to generate standing and stepping.
Study: NCT03508622

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth group sessions
Description: Telehealth sessions will utilize an online meeting platform and will be conducted by RDs, PTs, psychologists, and MDs, to deliver weight management information/counseling, to group of 5-6 14-18 yos with obesity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Empower clinic
Description: Empower visits for the retrospective control group were multi-disciplinary in nature, occurred at CHLA outpatient clinic, and were intended to be monthly (though actual adherence to recommended attendance was variable). Teen and minimum of one family member were asked to attend monthly visits, as per our standard clinical care.